Cargando…

Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma

PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication....

Descripción completa

Detalles Bibliográficos
Autores principales: Mayerhoefer, Marius E., Riedl, Christopher C., Kumar, Anita, Gibbs, Peter, Weber, Michael, Tal, Ilan, Schilksy, Juliana, Schöder, Heiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879438/
https://www.ncbi.nlm.nih.gov/pubmed/31286200
http://dx.doi.org/10.1007/s00259-019-04420-6
_version_ 1783473592351064064
author Mayerhoefer, Marius E.
Riedl, Christopher C.
Kumar, Anita
Gibbs, Peter
Weber, Michael
Tal, Ilan
Schilksy, Juliana
Schöder, Heiko
author_facet Mayerhoefer, Marius E.
Riedl, Christopher C.
Kumar, Anita
Gibbs, Peter
Weber, Michael
Tal, Ilan
Schilksy, Juliana
Schöder, Heiko
author_sort Mayerhoefer, Marius E.
collection PubMed
description PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. METHODS: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [(18)F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan–Meier estimates with log-rank tests were used for PFS prognostication. RESULTS: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high “metabolic risk”, was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). CONCLUSION: In MCL, the [(18)F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters.
format Online
Article
Text
id pubmed-6879438
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-68794382019-12-10 Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma Mayerhoefer, Marius E. Riedl, Christopher C. Kumar, Anita Gibbs, Peter Weber, Michael Tal, Ilan Schilksy, Juliana Schöder, Heiko Eur J Nucl Med Mol Imaging Original Article PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. METHODS: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [(18)F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan–Meier estimates with log-rank tests were used for PFS prognostication. RESULTS: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high “metabolic risk”, was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). CONCLUSION: In MCL, the [(18)F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters. Springer Berlin Heidelberg 2019-07-08 2019 /pmc/articles/PMC6879438/ /pubmed/31286200 http://dx.doi.org/10.1007/s00259-019-04420-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Mayerhoefer, Marius E.
Riedl, Christopher C.
Kumar, Anita
Gibbs, Peter
Weber, Michael
Tal, Ilan
Schilksy, Juliana
Schöder, Heiko
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title_full Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title_fullStr Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title_full_unstemmed Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title_short Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
title_sort radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879438/
https://www.ncbi.nlm.nih.gov/pubmed/31286200
http://dx.doi.org/10.1007/s00259-019-04420-6
work_keys_str_mv AT mayerhoefermariuse radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT riedlchristopherc radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT kumaranita radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT gibbspeter radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT webermichael radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT talilan radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT schilksyjuliana radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma
AT schoderheiko radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma